<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00543959</url>
  </required_header>
  <id_info>
    <org_study_id>0533-005</org_study_id>
    <secondary_id>MK0533-005</secondary_id>
    <secondary_id>2007_544</secondary_id>
    <nct_id>NCT00543959</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)</brief_title>
  <official_title>An Efficacy and Tolerability Study of MK0533 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A study to evaluate the effectiveness and tolerability of MK0533 and pioglitazone in patients
      with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study is being discontinued based on data suggesting that none of the doses tested
    demonstrated both glycemic &amp; body fluid benefits vs. the comparitor
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body fluid gain from baseline after 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose after 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">346</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Part1 - Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part1: Arm 1: drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 - Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part1 - Arm 2: Pbo comparator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 2 - Arm 1: Pbo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2- Arm 2: drug 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2 - Arm 3: drug 15mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2 - Arm 4: drug 30mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Arm 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 2 - Arm 5: active comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0533</intervention_name>
    <description>Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.</description>
    <arm_group_label>Part1 - Arm 1</arm_group_label>
    <arm_group_label>Part 2 - Arm 2</arm_group_label>
    <arm_group_label>Part 2 - Arm 3</arm_group_label>
    <arm_group_label>Part 2 - Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: Placebo (unspecified)</intervention_name>
    <description>MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.</description>
    <arm_group_label>Part1 - Arm 2</arm_group_label>
    <arm_group_label>Part 2 - Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: pioglitazone</intervention_name>
    <description>pioglitazone 45mg. Study period is a total of 24 wks.</description>
    <arm_group_label>Part 2 - Arm 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between the ages of 18 to 70 years with Type 2 diabetes who have not been
             able to adequately control their blood glucose levels

          -  Note: Only patients who have not been taking any antihyperglycemic medicine for 3
             months will be screened

        Exclusion Criteria:

          -  Patients taking any medicines that affect body fluid level such as a diuretic or water
             pill

          -  Patients taking niacin or other certain medications

          -  Patients with any of the following conditions: liver or kidney disease, poorly
             controlled high blood pressure, heart disease or certain blood disorders

          -  Patients with abnormal laboratory results from a blood test that will be given before
             each patient starts the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2007</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

